Teleflex Boosts 2025 Revenue Growth Outlook to 9%-10% Amid BIOTRONIK Acquisition and Tariff Mitigation

Teleflex Incorporated raised its 2025 revenue growth outlook to 9%-10% due to the BIOTRONIK acquisition and tariff mitigation. Q2 2025 revenues reached $780.9 million, a 4.2% YoY increase on a GAAP basis and 1% on an adjusted constant currency basis. The company's operational progress and value creation were emphasized by Chairman and CEO Liam J. Kelly.

Teleflex Incorporated (NYSE: TFX) reported strong second-quarter (Q2) 2025 financial results, with GAAP revenue reaching $780.9 million, up 4.2% year-over-year (YoY), and adjusted constant currency growth of 1.0% [1]. The company's Chairman, President, and CEO, Liam Kelly, highlighted the operational progress and value creation strategy. The acquisition of BIOTRONIK's Vascular Intervention business has significantly impacted the company's financial outlook, with full-year 2025 revenue growth guidance raised to 9.00% to 10.00% and adjusted constant currency revenue growth to 7.70% to 8.70% [1].

The Q2 2025 results showed mixed segment performance. The Americas region saw revenue growth of 1.9%, while EMEA and Asia grew by 13.0% and 2.3%, respectively. The Interventional category emerged as the star performer with 20.4% growth, while OEM and Interventional Urology experienced declines of 11.4% and 8.1%, respectively [1]. Despite these mixed results, the company's adjusted diluted earnings per share (EPS) reached $3.73, a 9.1% increase from the prior year period [1].

The acquisition of BIOTRONIK's Vascular Intervention business is expected to contribute $204 million in revenue in the second half of 2025, significantly impacting the company's full-year revenue and EPS guidance [1]. The acquisition aligns with Teleflex's strategy to expand its global presence in the cath lab and establish a footprint in the growing peripheral intervention market [1].

However, the balance sheet shows some mixed signals. Cash decreased to $283.9 million from $327.7 million at year-end 2024, while inventories increased by 15.6% to $693.7 million and accounts receivable rose by 11.8% to $513.8 million, suggesting potential working capital challenges that bear watching [1].

Chairman Kelly emphasized the company's focus on unlocking shareholder value through the separation of "NewCo" and actively exploring options to maximize shareholder value creation [1]. Teleflex continues to make progress in its value creation strategy across its business, with the acquisition of BIOTRONIK's Vascular Intervention business driving the increase in 2025 adjusted constant currency revenue guidance [1].

References:
[1] Teleflex Incorporated. (2025, July 31). Teleflex Reports Second Quarter 2025 Financial Results and Full-Year 2025 Guidance. Retrieved from https://www.stocktitan.net/news/TFX/teleflex-reports-second-quarter-financial-results-and-full-year-2025-h9g5vps2nw06.html